N@N

UTHR, NUS, ESI, SGMO, Expected to Trade Lower After Bearish Insider Trading

^{Published on 2011-06-07 06:30:39 - WOPRAI}
 

June 7, 2011 / M2 PRESSWIRE / BUYINS.NET / http://www.squeezetrigger.com is monitoring top insider trading patterns and these stocks are the most likely to trade Lower in the next 6 months. UNITED THERAPEUTICS CORPORATION (NASDAQ:UTHR), NU SKIN ENTERPRISES INC - A (NYSE:NUS), ITT EDUCATIONAL SERVICES INC (NYSE:ESI), SANGAMO BIOSCIENCES, INC. (NASDAQ:SGMO) are all expected to go Lower as Sell signals have been generated by top insider trading patterns. The most important data elements considered when performing insider analysis are: Insiders Track Record - An insiders track record is best summarized by the Insider Score which ranges from 1 (least predictive) to 100 (most predictive) based on prior trading performance. In addition, the actual returns following the insiders prior trades are included to determine the potential magnitude of future returns. Insiders Role - Trades by higher-level insiders are generally more predictive than trades by lower level insiders. Higher-level insiders to include Chairman (CB), Chief Executive Officer (CEO), President (P), Chief Financial Officer (CFO), and Vice Chairman (VC).

The chart below displays the stocks expected to go Lower along with the insider name, position, predictive insider score, 6 month expected return and number of trading decisions included in the score.

     Symbol     Company Name                        Insider Name                        Role        Shares         Insider Score     Avg 6 Month Return     # of Dec. 
     UTHR       UNITED THERAPEUTICS CORPORATION     Ferrari, John Maxim                 CFO         5,500          87                -5.0%                  40        
     NUS        NU SKIN ENTERPRISES INC - A         Wood, Ritch N                       CFO         40,000         90                -10.1%                 5         
     ESI        ITT EDUCATIONAL SERVICES INC        Van, Buren Martin                   CT          3,000          89                -47.1%                 3         
     SGMO       SANGAMO BIOSCIENCES, INC.           Gregory, Philip D                   O           15,000         100               -35.1%                 20        

UNITED THERAPEUTICS CORPORATION (NASDAQ:UTHR) - United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of therapeutic products for patients with chronic and life-threatening diseases in the United States and Internationally. It offers Remodulin, Tyvaso, and Adcirca (tadalafil) tablets for the treatment of pulmonary arterial hypertension (PAH); and CardioPAL SAVI and decipher cardiac monitors, and CardioPAL SAVI wireless cardiac event monitors for cardiac arrhythmias and ischemic heart disease. The companys under development products include Oral Treprostinil, which is in Phase III clinical trials for the treatment of PAH and is in Phase II clinical trials for the treatment of peripheral vascular disease; Beraprost-MR, a Phase II clinical trials product for the treatment of PAH; 3F8 MAb, a Phase II clinical trials product for neuroblastoma; Aviptadil, a Phase II clinical trials product targeting pulmonary hypertension and other pulmonary diseases; 8H9 MAb, a Phase I clinical trials product for the treatment of metastatic brain cancer; IW001, a Phase I clinical trials product that targets idiopathic pulmonary fibrosis and primary graft dysfunction; and Glycobiology Antiviral Agents, which are in pre-clinical trials for Hepatitis C and other infectious diseases. United Therapeutics Corporation also provides telemedicine monitoring services to detect cardiac arrhythmias and ischemic heart disease. The company sells its products through sales and marketing staff, specialty pharmaceutical distributors, and pharmaceutical wholesalers. It has a licensing agreements and relationships with Eli Lilly and Company; Toray Industries, Inc.; NEBU-TEC; Mondobiotech; ImmuneWorks; GlaxoSmithKline PLC; Pfizer Inc.; and Supernus Pharmaceuticals, Inc. The company was formerly known as Lung Rx, Inc. and changed its name in December, 1997. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.

NU SKIN ENTERPRISES INC - A (NYSE:NUS) - Nu Skin Enterprises, Inc. develops and distributes anti-aging personal care products and nutritional supplements worldwide. The company sells its personal care products under the Nu Skin brand; and nutritional supplements under the Pharmanex brand. Its personal care product line includes core systems, targeted treatments, total care, cosmetic, and Epoch, a product formulated with botanical ingredients. The companys nutritional supplements product line comprises micronutrient supplements, targeted solution supplements, and weight management products. It also sells Vitameal, which are nutritious meal products for starving children or purchased for personal food storage. In addition, the company offers other products and services consisting of digital content storage, water purifiers, and other household products. It sells its products primarily through a network of independent distributors in north Asia, the Americas, Greater China, Europe, and the south Asia/Pacific. The company also operates retail stores to sell its products in China. As of December 31, 2010, Nu Skin Enterprises operated 40 stores throughout China. The company was founded in 1984 and is headquartered in Provo, Utah.

ITT EDUCATIONAL SERVICES INC (NYSE:ESI) - itt Educational Services Inc. offers postsecondary-degree programs in the U.S. that provide diplomas as well as associates, bachelors, and masters degrees in information technology, electronics technology, drafting and design, business, criminal justice, and health sciences. As of Mar. 22, the company operated 90 itt Technical Institutes in 33 states that primarily offer career-oriented degree programs to about 47,000 students. Headquartered in Carmel, Ind., itt was started in 1946.

SANGAMO BIOSCIENCES, INC. (NASDAQ:SGMO) - Sangamo Biosciences, Inc. engages in the research, development, and commercialization of zinc finger DNA-binding proteins (ZFPs) for gene regulation and gene modification in the United States. Its ZFPs could be engineered to make ZFP transcription factors (ZFP TFs), proteins that could be used to turn genes on or off; and ZFP nucleases (ZFNs), proteins that enable to modify DNA sequences in various ways. The companys principal ZFP therapeutic include SB-509, a plasmid formulation of a ZFP TF activator of the vascular endothelial growth factor-A (VEGF-A) gene that is in a Phase 2b clinical trial for the treatment of severe diabetic neuropathy; and in a Phase 2 clinical trial in for the treatment of amyotrophic lateral sclerosis, as well as in preclinical animal studies for spinal cord injury, traumatic brain injury, and stroke. It is also developing SB-728-T, a ZFN-modified T-cell product, which is in Phase 1/2 clinical trial and two Phase 1 trials for the treatment of HIV/AIDS. In addition, the company develops SB-313xTZ, a ZFN-based therapeutic that is in Phase 1 clinical trial for the treatment of glioblastoma multiforme, a type of brain cancer. Further, it has preclinical development programs of ZFP therapeutics in the areas of Parkinsons disease, hemophilia B, and neuropathic pain; and neuroregenerative programs in spinal cord injury, traumatic brain injury, and stroke. Additionally, the company has research stage programs in the areas of monogenic diseases and genetic conditions that result from a defect in a single gene, including hemophilia and other hemoglobinopathies, and immunodeficiencies. It has collaboration agreements with Sigma-Aldrich Corporation; Dow AgroSciences LLC; Pfizer Inc.; Genentech, Inc.; Open Monoclonal Technology, Inc.; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. The company was founded in 1995 and is headquartered in Richmond, California.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

Insider Trading tracks all insider trades and selects those insider buys that predict higher moves and insider sales that predict lower moves.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net